

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8283832

|                                   |                                                |
|-----------------------------------|------------------------------------------------|
| <b>SUBMISSION TYPE:</b>           | NEW ASSIGNMENT                                 |
| <b>NATURE OF CONVEYANCE:</b>      | SECURITY INTEREST                              |
| <b>CONVEYING PARTY DATA</b>       |                                                |
| <b>Name</b>                       | <b>Execution Date</b>                          |
| AMNEAL PHARMACEUTICALS LLC        | 11/14/2023                                     |
| <b>RECEIVING PARTY DATA</b>       |                                                |
| <b>Name:</b>                      | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT |
| <b>Street Address:</b>            | 10 S. DEARBORN STREET                          |
| <b>City:</b>                      | CHICAGO                                        |
| <b>State/Country:</b>             | ILLINOIS                                       |
| <b>Postal Code:</b>               | 60603                                          |
| <b>PROPERTY NUMBERS Total: 26</b> |                                                |
| <b>Property Type</b>              | <b>Number</b>                                  |
| Application Number:               | 15935894                                       |
| Application Number:               | 17041886                                       |
| Application Number:               | 13661800                                       |
| Application Number:               | 14935003                                       |
| Application Number:               | 15426136                                       |
| Application Number:               | 16105615                                       |
| Application Number:               | 16544128                                       |
| Application Number:               | 16524664                                       |
| Application Number:               | 18122515                                       |
| Application Number:               | 17630297                                       |
| Application Number:               | 17489343                                       |
| Application Number:               | 17861844                                       |
| Application Number:               | 17525298                                       |
| Application Number:               | 17984001                                       |
| Application Number:               | 63453187                                       |
| Application Number:               | 17959681                                       |
| Application Number:               | 29475938                                       |
| Application Number:               | 29520806                                       |
| Application Number:               | 29520841                                       |
| Application Number:               | 18240029                                       |

| Property Type       | Number    |
|---------------------|-----------|
| Application Number: | 16637114  |
| Application Number: | 17558337  |
| Application Number: | 17967332  |
| Application Number: | 13226061  |
| Application Number: | 14052116  |
| PCT Number:         | US2236975 |

#### CORRESPONDENCE DATA

**Fax Number:** (212)751-4864

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2129061209

**Email:** jess.bajada-bartlett@lw.com

**Correspondent Name:** LATHAM & WATKINS C/O JESSICA BAJADA-BARTLETT

**Address Line 1:** 1271 AVENUE OF THE AMERICAS

**Address Line 4:** NEW YORK, NEW YORK 10020

|                                |                             |
|--------------------------------|-----------------------------|
| <b>ATTORNEY DOCKET NUMBER:</b> | 045494-0508                 |
| <b>NAME OF SUBMITTER:</b>      | JESSICA BAJADA-BARTLETT     |
| <b>SIGNATURE:</b>              | /s/ Jessica Bajada-Bartlett |
| <b>DATE SIGNED:</b>            | 11/17/2023                  |

#### Total Attachments: 10

source=New Patent Security Agreement FINAL [Executed]#page1.tif  
source=New Patent Security Agreement FINAL [Executed]#page2.tif  
source=New Patent Security Agreement FINAL [Executed]#page3.tif  
source=New Patent Security Agreement FINAL [Executed]#page4.tif  
source=New Patent Security Agreement FINAL [Executed]#page5.tif  
source=New Patent Security Agreement FINAL [Executed]#page6.tif  
source=New Patent Security Agreement FINAL [Executed]#page7.tif  
source=New Patent Security Agreement FINAL [Executed]#page8.tif  
source=New Patent Security Agreement FINAL [Executed]#page9.tif  
source=New Patent Security Agreement FINAL [Executed]#page10.tif

## PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT is dated as of November 14, 2023, by AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company, IMPAX LABORATORIES, LLC, a Delaware limited liability company and GEMINI LABORATORIES, LLC, a Delaware limited liability company (each, individually, a "Grantor" and, collectively, the "Grantors"), in favor of JPMorgan Chase Bank, N.A., in its capacity as administrative agent and collateral agent (in such capacity, the "Collateral Agent").

### WITNESSETH:

WHEREAS, the Grantors are party to that certain Term Loan Guarantee and Collateral Agreement dated as of November 14, 2023 (as amended, amended and restated, supplemented, refinanced, replaced, extended or otherwise modified from time to time, the "Security Agreement") in favor of the Collateral Agent, pursuant to which the Grantors are required to execute and deliver this Patent Security Agreement.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the meanings given to them in the Security Agreement.

SECTION 2. Grant of Security Interest in Patent Collateral. As security for the payment or performance when due (whether at stated maturity, by acceleration or otherwise), as the case may be, in full of the Secured Obligations, each Grantor hereby pledges to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, and hereby grants to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, a security interest in all of such Grantor's right, title, and interest in or to any and all of the following Intellectual Property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the "Patent Collateral"), including:

- (a) all Patents issued or applied for in the United States, including those listed on Schedule I;
- (b) all provisionals, reissues, extensions, continuations, divisions, continuations-in-part, reexaminations or revisions thereof, and the inventions disclosed or claimed therein, including the right to make, use, import and/or sell the inventions disclosed or claimed therein;
- (c) all claims for, and rights to sue for, past or future infringements of any of the foregoing; and

- (d) all income, royalties, damages and payments now or hereafter due and payable with respect to any of the foregoing, including damages and payments for past or future infringement thereof.

SECTION 3. Security Agreement. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent pursuant to the Security Agreement and the Grantors hereby acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Recordation. This Patent Security Agreement has been executed and delivered by the Grantors for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The Grantor authorizes and requests that the Commissioner of Patents record this Patent Security Agreement.


SECTION 5. Counterparts. This Patent Security Agreement may be executed in one or more counterparts, each of which shall constitute an original but all of which, when taken together, shall constitute but one contract. Delivery of an executed counterpart to this Patent Security Agreement by facsimile or other electronic transmission (e.g., "PDF" or "TIFF") shall be as effective as delivery of a manually signed original.

SECTION 6. Governing Law. THIS PATENT SECURITY AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (EXCEPT FOR CONFLICTS OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION).

*[Signature page follows]*

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.


**AMNEAL PHARMACEUTICALS LLC,**  
as Grantor

By: 

Name: Anastasios Konidaris

Title: Executive Vice  
President and Chief  
Financial Officer


**IMPAX LABORATORIES, LLC,**  
as Grantor

By: 

Name: Anastasios Konidaris

Title: Executive Vice  
President and Chief  
Financial Officer

**GEMINI LABORATORIES, LLC**  
as Grantor

By: 

Name: Anastasios Knoidaris

Title: Executive Vice  
President and Chief  
Financial Officer

Accepted and Agreed:

**JPMORGAN CHASE BANK, N.A.,**  
as Collateral Agent

By: William R. Doolittle

Name: William R. Doolittle

Title: Executive Director

[Signature Page to Term Loan Patent Security Agreement]

**PATENT**  
**REEL: 065602 FRAME: 0697**

**SCHEDULE I**  
to  
**PATENT SECURITY AGREEMENT**  
**PATENTS AND PATENT APPLICATIONS**

|    | <b>Patent Title</b>                                                               | <b>Country Name</b>      | <b>Application Number Filing Date</b> | <b>Patent Number Grant Date</b> | <b>Owner</b>                                                             |
|----|-----------------------------------------------------------------------------------|--------------------------|---------------------------------------|---------------------------------|--------------------------------------------------------------------------|
| 1. | METHOD FOR THE PREPARATION OF CINACALCET AND INTERMEDIATES AND IMPURITIES THEREOF | United States of America | 13/226061<br>06-Sep-2011              | 8575395<br>05-Nov-2013          | AMNEAL PHARMACEUTICALS LLC (jointly owned with Megafine Pharma (P) Ltd.) |
| 2. | METHOD FOR THE PREPARATION OF CINACALCET AND INTERMEDIATES AND IMPURITIES THEREOF | United States of America | 14/052116<br>11-Oct-2013              | 8969623<br>03-Mar-2015          | AMNEAL PHARMACEUTICALS LLC (jointly owned with Megafine Pharma (P) Ltd.) |
| 3. | KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLING   | United States of America | 15/935894<br>26-Mar-2018              | 10434248<br>08-Oct-2019         | AMNEAL PHARMACEUTICALS LLC                                               |
| 4. | KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLING   | United States of America | 17/041886<br>25-Sep-2020              |                                 | AMNEAL PHARMACEUTICALS LLC                                               |
| 5. | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME                                 | United States of America | 13/661800<br>26-Oct-2012              | 9180108<br>10-Nov-2015          | AMNEAL PHARMACEUTICALS LLC                                               |
| 6. | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME                                 | United States of America | 14/935003<br>06-Nov-2015              | 9597304<br>21-Mar-2017          | AMNEAL PHARMACEUTICALS LLC                                               |
| 7. | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME                                 | United States of America | 15/426136<br>07-Feb-2017              | 10076506<br>18-Sep-2018         | AMNEAL PHARMACEUTICALS LLC                                               |
| 8. | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME                                 | United States of America | 16/105615<br>20-Aug-2018              | 10420740<br>24-Sep-2019         | AMNEAL PHARMACEUTICALS LLC                                               |
| 9. | BACLOFEN FORMULATIONS AND                                                         | United States of America | 16/544128<br>19-Aug-2019              | 10813900<br>27-Oct-2020         | AMNEAL PHARMACEUTICALS LLC                                               |

|     | Patent Title                                                                                       | Country Name             | Application Number Filing Date | Patent Number Grant Date | Owner                      |
|-----|----------------------------------------------------------------------------------------------------|--------------------------|--------------------------------|--------------------------|----------------------------|
|     | METHODS FOR MAKING SAME                                                                            |                          |                                |                          |                            |
| 10. | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES                         | United States of America | 16/524664<br>29-Jul-2019       | 10792262<br>06-Oct-2020  | AMNEAL PHARMACEUTICALS LLC |
| 11. | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES                         | United States of America | 18/122515<br>16-Mar-2023       |                          | AMNEAL PHARMACEUTICALS LLC |
| 12. | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES                         | United States of America | 17/630297<br>26-Jan-2022       | 11654124<br>23-May-2023  | AMNEAL PHARMACEUTICALS LLC |
| 13. | IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | United States of America | 17/489343<br>29-Sep-2021       | 11491125<br>08-Nov-2022  | AMNEAL PHARMACEUTICALS LLC |
| 14. | IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | United States of America | 17/861844<br>11-Jul-2022       |                          | AMNEAL PHARMACEUTICALS LLC |
| 15. | IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | United States of America | PCT/US22/36975<br>13-Jul-2022  |                          | AMNEAL PHARMACEUTICALS LLC |
| 16. | COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN                                                 | United States of America | 17/525298<br>12-Nov-2021       | 11523984<br>13 Dec-2022  | AMNEAL PHARMACEUTICALS LLC |
| 17. | COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN                                                 | United States of America | 17/984001<br>9-Nov-2022        |                          | AMNEAL PHARMACEUTICALS LLC |



|     | Patent Title                                                 | Country Name             | Application Number Filing Date | Patent Number Grant Date | Owner                      |
|-----|--------------------------------------------------------------|--------------------------|--------------------------------|--------------------------|----------------------------|
| 18. | IMMUNO SUPPRESSIVE DOSAGE FORMS AND METHODS OF USE           | United States of America | 17/506748<br>21-Oct-2021       |                          | GEMINI LABORATORIES, LLC   |
| 19. | IMMUNO SUPPRESSIVE DOSAGE FORMS AND METHODS OF USE           | United States of America | 63/453187<br>20-Mar-2023       |                          | AMNEAL PHARMACEUTICALS LLC |
| 20. | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF | United States of America | 12/599668<br>10-Nov-2009       | 8377474<br>19-Feb-2013   | IMPAX LABORATORIES, LLC    |
| 21. | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF | United States of America | 13/711248<br>11-Dec-2012       | 8557283<br>15-Oct-2013   | IMPAX LABORATORIES, LLC    |
| 22. | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF | United States of America | 13/900408<br>22-May-2013       | 9089607<br>28-Jul-2015   | IMPAX LABORATORIES, LLC    |
| 23. | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF | United States of America | 14/030792<br>18-Sep-2013       | 9089608<br>28-Jul-2015   | IMPAX LABORATORIES, LLC    |
| 24. | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF | United States of America | 14/030813<br>18-Sep-2013       | 9463246<br>11-Oct-2016   | IMPAX LABORATORIES, LLC    |
| 25. | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF | United States of America | 14/958975<br>04-Dec-2015       | 9533046<br>03-Jan-2017   | IMPAX LABORATORIES, LLC    |
| 26. | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF | United States of America | 15/382851<br>19-Dec-2016       | 9901640<br>27-Feb-2018   | IMPAX LABORATORIES, LLC    |
| 27. | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF | United States of America | 13/367230<br>06-Feb-2012       | 8454998<br>04-Jun-2013   | IMPAX LABORATORIES, LLC    |

|     | Patent Title                                                                                         | Country Name             | Application Number Filing Date | Patent Number Grant Date | Owner                   |
|-----|------------------------------------------------------------------------------------------------------|--------------------------|--------------------------------|--------------------------|-------------------------|
| 28. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | United States of America | 15/027654<br>06-Apr-2016       | 10098845<br>16-Oct-2018  | IMPAX LABORATORIES, LLC |
| 29. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | United States of America | 15/092086<br>06-Apr-2016       | 10292935<br>21-May-2019  | IMPAX LABORATORIES, LLC |
| 30. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | United States of America | 16/573634<br>17-Sep-2019       | 10987313<br>27-Apr-2021  | IMPAX LABORATORIES, LLC |
| 31. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | United States of America | 17/148320<br>13-Jan-2021       | 11357733<br>14-Jun-2022  | IMPAX LABORATORIES, LLC |
| 32. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | United States of America | 17/372434<br>10-Jul-2021       | 11622941<br>11-Apr-2023  | IMPAX LABORATORIES, LLC |
| 33. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | United States of America | 17/959681<br>04-Oct-2022       | 11666538<br>06-Jun-2023  | IMPAX LABORATORIES, LLC |
| 34. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR                                     | United States of America | 16/360936<br>21-Mar-2019       | 10688058<br>23-Jun-2020  | IMPAX LABORATORIES, LLC |

|     | Patent Title                                                                                                                  | Country Name             | Application Number Filing Date | Patent Number Grant Date | Owner                      |
|-----|-------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------------|--------------------------|----------------------------|
|     | ESTERS OF LEVODOPA AND USES THEREOF                                                                                           |                          |                                |                          |                            |
| 35. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF                          | United States of America | 16/864323<br>01-May-2020       | 10973769<br>13-Apr-2021  | IMPAX LABORATORIES, LLC    |
| 36. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF                          | United States of America | 18/131715<br>06-April-2023     |                          | IMPAX LABORATORIES, LLC    |
| 37. | MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF                          | United States of America | 17/959681<br>04-Oct-2022       | 1166538                  | AMNEAL PHARMACEUTICALS LLC |
| 38. | Applicator for applying a liquid to a surface                                                                                 | United States of America | 29475938<br>09-Dec-2013        | D752287<br>22-Mar-2016   | AMNEAL PHARMACEUTICALS LLC |
| 39. | Inhalation device                                                                                                             | United States of America | 29520806<br>18-Mar-2015        | D769439<br>18-Oct-2016   | AMNEAL PHARMACEUTICALS LLC |
| 40. | Inhalation device                                                                                                             | United States of America | 29520841<br>18-Mar-2015        | D767114<br>2016-Sep-20   | AMNEAL PHARMACEUTICALS LLC |
| 41. | Refill Kit for Implantable Pump                                                                                               | United States of America | 18/240,029<br>30-Aug-2023      |                          | AMNEAL PHARMACEUTICALS LLC |
| 42. | SIMULTANEOUS USE OF IMAGING AND ENHANCED NEEDLES OR DEVICES TO IMPROVE SAFETY OF IMPLANTABLE PUMP REFILLS AND TROUBLESHOOTING | United States of America | 16/637,114<br>06-Feb-2020      |                          | AMNEAL PHARMACEUTICALS LLC |
| 43. | LEVODOPA DOSING REGIMEN                                                                                                       | United States of America | 17/558,337<br>21-Dec-2021      |                          | AMNEAL PHARMACEUTICALS LLC |

|     | Patent Title            | Country Name             | Application Number Filing Date | Patent Number Grant Date | Owner                      |
|-----|-------------------------|--------------------------|--------------------------------|--------------------------|----------------------------|
| 44. | LEVODOPA DOSING REGIMEN | United States of America | 17/967,332<br>17-Oct-2022      |                          | AMNEAL PHARMACEUTICALS LLC |